Comparison of Back-Propagation Neural Network, LACE Index and HOSPITAL Score in Predicting All-Cause Risk of 30-Day Readmission

by Lin C, Hsu S, Lu HF, Pan LF, Yan YH
Published 2021-09-01

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials

by Cai SL, Lu HF, Bai ZH, Wu RR, Zhao JP
Published 2015-07-01

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral a...

by Li N, Feng Y, Lu HF, Cai SL, Zhuo JM, Si TM, Zhang LL
Published 2018-03-01

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

by Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Published 2017-08-01